Veraxa Biotech advances bispecific ADC program VXA-222 into next development phase after OmniAb milestonePUBT·1 day ago, 03:17 PMVRXA+1.26%OABI-0.25%
VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAbUnusual Whales·2 days ago, 06:02 AMVRXA+1.26%OABI-0.25%
Veraxa Biotech shareholders approved all proposals at extraordinary general meetingPUBT·Jul 24 at 03:05 PMVRXA+1.26%
VERAXA Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth | VRXA Stock NewsStockTitan·Jul 24 at 07:05 AMVRXA+1.26%
Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick AustinPUBT·Jul 23 at 06:02 AMVRXA+1.26%
Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development planPUBT·Jul 20 at 06:01 AMVRXA+1.26%
VERAXA Biotech (NASDAQ: VRXA) Partners With Ardigen to Advance AI-Driven Cancer Drug Developmentbusinessinsider·Jul 13 at 12:15 PMVRXA+1.26%
AI Chips Today - AI Advancements Revolutionize Drug Discovery and Cancer TreatmentSimplywall·Jul 13 at 08:16 AMMU-5.25%SKHY-1.91%
Veraxa Biotech partners with Ardigen on AI-enabled drug discovery for BiTAC pipelinePUBT·Jul 13 at 06:00 AMVRXA+1.26%
FB Financial, Smith Micro Software And 3 Stocks To Watch Heading Into Mondaybenzinga_article·Jul 13 at 01:35 AMLGPS-4.19%VRXA+1.26%
Veraxa Biotech names Carl von Halem interim CFO, replacing Torsten BürgermeisterPUBT·Jul 10 at 03:22 PMVRXA+1.26%
